NurOwn and the Hope for Stem Cells in ALS?
Oct 15, 2019•13 min•Season 1Ep. 14
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
On this episode of the Endpoints, Dr. Steve Perrin, CEO at ALS TDI answers questions about one of the most talked about clinical trials in ALS at the moment, Brainstorm Cell Therapeutics’ NurOwn, a proposed stem-cell-based treatment. The therapy focuses on the cellular support system around a person with ALS’ motor neurons. It aims to slow disease progression by replacing the damaged system with an enhanced one.
To listen to more episodes of the Endpoints Podcast, click here.
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android